Metformin hydrochloride enteric-coated preparation
AssigneeYayan (Tianjin) Biomedical Technology Center (Limited Partnership)
InventorsQian GAO, Wei WANG, Tao DONG
Life of this patent
Estimating the term…
Loading patent…
AssigneeYayan (Tianjin) Biomedical Technology Center (Limited Partnership)
InventorsQian GAO, Wei WANG, Tao DONG
Estimating the term…
An enteric-coated preparation of metformin hydrochloride, which is an oral dosage form made of a therapeutically effective amount of a biguanide compound and a pharmaceutically acceptable excipient. The said enteric-coated preparation of metformin hydrochloride has a dissolution rate of no more than 15% in a pH 4.5 medium within 120 minutes, and a dissolution rate of no less than 85% in a pH 6.8 medium within 20 minutes, preferably a dissolution rate of no more than 7.5% in a pH 4.5 medium within 120 minutes, and a dissolution rate of no less than 85% in a pH 6.8 medium within 15 minutes. The enteric-coated preparation of metformin hydrochloride with the drug dissolution technology improves the gastrointestinal tolerance of metformin hydrochloride without reducing or even improving the hypoglycemic efficacy, reduces adverse reactions caused by the drug, and can be taken before, after or during meals.
An enteric-coated preparation of a biguanide compound, which is an oral dosage form made of a therapeutically effective amount of a biguanide compound and a pharmaceutically acceptable excipient, characterized in that:
Dependencies are inferred from the claim text.